Vande Griend Joseph P, Linnebur Sunny A, Bainbridge Jacquelyn L
Department of Clinical Pharmacy, School of Pharmacy, University of Colorado Denver, Aurora, Colorado 80045, USA.
Am J Geriatr Pharmacother. 2009 Oct;7(5):281-4. doi: 10.1016/j.amjopharm.2009.10.002.
Compared with traditional antiepileptic drugs, levetiracetam has a unique mechanism of action and unique properties, including predominant renal excretion and lack of drug-drug interactions. In the elderly, depression associated with levetiracetam has not been reported.
A 73-year-old black man (height, 172.7 cm; weight, 92.7 kg; body mass index [BMI], 31 kg/m(2)) with stage 4 kidney disease was taking levetiracetam 500 mg BID for partial complex seizures. After 5 months of taking medication, new-onset depression, evidenced by depressed mood, weight loss, fatigue, and appearing withdrawn, was noted in this patient. Levetiracetam was discontinued by order of the patient's primary care physician. At a follow-up appointment 4 weeks later, the depressive symptoms had nearly resolved. The patient's Naranjo Adverse Drug Reaction Probability Scale score was 6, indicating levetiracetam to be a probable cause of depression in this patient. In a second case, a 92-year-old white woman (height, 154.9 cm; weight, 54.5 kg; BMI, 22.7 kg/m(2)) with existing chronic kidney disease and new-onset partial seizure, likely due to a meningioma, was initiated on levetiracetam 500 mg once daily. Depressive symptoms (eg, anhedonia, hypersomnolence, decreased appetite) were noted within 5 weeks. Cessation led to improvement in mood and cognition within 8 days. Based on this patient's Naranjo Adverse Drug Reaction Probability Scale score of 6, levetiracetam was a probable cause of depression in this patient.
Levetiracetam was a probable cause of depression in these 2 elderly patients. Cautious use and additional monitoring may be necessary when prescribing levetiracetam to elderly patients, especially when prescribing to those with a history of renal impairment.
与传统抗癫痫药物相比,左乙拉西坦具有独特的作用机制和特性,包括主要经肾脏排泄以及不存在药物相互作用。在老年人中,尚未有与左乙拉西坦相关的抑郁症报道。
一名73岁黑人男性(身高172.7厘米;体重92.7千克;体重指数[BMI]为31千克/米²)患有4期肾病,正在服用左乙拉西坦500毫克,每日两次,用于治疗部分性癫痫发作。服药5个月后,该患者出现新发抑郁症,表现为情绪低落、体重减轻、疲劳以及行为退缩。患者的初级保健医生下令停用左乙拉西坦。4周后的随访预约时,抑郁症状几乎消失。该患者的纳伦霍药物不良反应概率量表评分为6分,表明左乙拉西坦可能是该患者抑郁症的病因。在第二个病例中,一名92岁白人女性(身高154.9厘米;体重54.5千克;BMI为22.7千克/米²)患有慢性肾病且新发部分性癫痫发作,可能是由于脑膜瘤所致,开始服用左乙拉西坦500毫克,每日一次。5周内出现了抑郁症状(如快感缺失、嗜睡、食欲减退)。停药后8天内情绪和认知得到改善。基于该患者的纳伦霍药物不良反应概率量表评分为6分,左乙拉西坦可能是该患者抑郁症的病因。
左乙拉西坦可能是这2例老年患者抑郁症的病因。在给老年患者开左乙拉西坦处方时,尤其是给有肾功能损害病史的患者开处方时,可能需要谨慎使用并加强监测。